2-iminobiotin (2-IB)
Cerebral hypoxia-ischemia following Stroke
Key Facts
About Neurophyxia
Neurophyxia is a private, clinical-stage Dutch biotech advancing 2-iminobiotin (2-IB), a novel neuroprotectant, into a Phase IIb/III trial for cerebral hypoxia-ischemia following stroke, with secondary indications in cardiac arrest and birth asphyxia. Founded on academic research, the company is managed by a lean team of founders and specialized consultants with deep pharmaceutical development experience. As a pre-revenue entity, its near-term value inflection hinges on the success of its pivotal clinical program for a significant unmet medical need in neuroprotection.
View full company profileAbout Neurophyxia
Neurophyxia is a private, clinical-stage Dutch biotech advancing 2-iminobiotin (2-IB), a novel neuroprotectant, into a Phase IIb/III trial for cerebral hypoxia-ischemia following stroke, with secondary indications in cardiac arrest and birth asphyxia. Founded on academic research, the company is managed by a lean team of founders and specialized consultants with deep pharmaceutical development experience. As a pre-revenue entity, its near-term value inflection hinges on the success of its pivotal clinical program for a significant unmet medical need in neuroprotection.
View full company profileAbout Neurophyxia
Neurophyxia is a private, clinical-stage Dutch biotech advancing 2-iminobiotin (2-IB), a novel neuroprotectant, into a Phase IIb/III trial for cerebral hypoxia-ischemia following stroke, with secondary indications in cardiac arrest and birth asphyxia. Founded on academic research, the company is managed by a lean team of founders and specialized consultants with deep pharmaceutical development experience. As a pre-revenue entity, its near-term value inflection hinges on the success of its pivotal clinical program for a significant unmet medical need in neuroprotection.
View full company profile